RxDoctor Payments Data

Sandhya Venugopal, MD

Cardiovascular Disease · Sacramento, CANPI 1013921253

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 44 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Recor Medical Inc$282
  • Biotronik Inc.$231
  • Amgen$145
  • Pfizer$120
  • Medtronic$86
  • E.r. Squibb & Sons, L.L.C.$55
  • plus $431 from 14 others

What the payments were for

  • Food & beverage$1,33699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,350 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$121,589
Medicare patients
2,515
Services billed
3,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$129,525
JardianceEmpagliflozin31$35,116
EntrestoSacubitril/Valsartan37$33,640
XareltoRivaroxaban24$29,829
Dofetilide18$3,119
Amiodarone Hcl18$2,039
Metoprolol Succinate123$2,004
Atorvastatin Calcium69$1,261
Rosuvastatin Calcium43$670
Losartan Potassium39$580
Carvedilol43$564
Spironolactone52$515
Amlodipine Besylate81$460
Lisinopril23$279
Metoprolol Tartrate20$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$129,52589 claims
Boehringer IngelheimJardiance$21$35,11631 claims
NovartisEntresto$18$33,64037 claims
Johnson & JohnsonXarelto$53$29,82924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →